Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G(1) block at concentrations up to 100-fold the IC(50) for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
1 retracted
Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Davis, S. T., Benson, B. G., Bramson, H. N., Chapman, D. E., Dickerson, S. H., Dold, K. M., Eberwein, D. J., Edelstein, M., Frye, S. V., Gampe, R. T., et al. (2001) · Science · doi:10.1126/science.291.5501.134 · Cited by 166
RetractedThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Synthesis of Macroporous Minerals with Highly Ordered Three-Dimensional Arrays of Spheroidal Voids
Holland, B. T., Blanford, C. F., & Stein, A. (1998) · Science · doi:10.1126/science.281.5376.538 · Cited by 1,484
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 809
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Research works printed but not linked: 46
- Fisher P. M., 2003, Expert. Opin. Investig. Drugs, 12, 970
- Fisher P. M, 2001, Curr. Opin. Drug Discuss. Dev., 4, 634
- Fry D. W., 2000, Curr. Opin. Oncol., Endocrine Metab. Invest. Drugs, 2, 59
- Gray N., 1999, Curr. Med. Chem., 6, 875
- Fry D. W., 2001, J. Biol. Chem., 276, 16623
- Wang S., 2001, Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry
- Chang Y.-T., 1999, Chem. Biol., 6, 375
- Schow S. R., 1997, Bioorg. Med. Chem. Lett., 7, 2702
- Zaharevitz D. W., 1999, Cancer Res., 59, 2569
- Gussio R., 2000, Anti-Cancer Drug Des., 15, 66
- Kunick C., 2000, Bioorg. Med. Chem. Lett., 10, 569, 10.1016/S0960-894X(00)00048-2 · DOI
- Tang J., 2003, Bioorg. Med. Chem. Lett., 13, 2988
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 2408
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 1136
- Song Y., 2002, Bioorg. Med. Chem. Lett., 12, 1132
- Kim K. S., 2002, J. Med. Chem., 45, 3927
- Furet P., 2002, Bioorg. Med. Chem. Lett., 12, 224
- Sielecki T. M., 2001, Bioorg. Med. Chem. Lett., 11, 1160
- Sasaki S., 1998, Bioorg. Med. Chem. Lett., 8, 1022
- Seong Y.-S., 2003, Cancer Res., 63, 7391
- Kim K. S., 2000, J. Med Chem., 43, 4134
- Li X., 2003, Bioorg. Med. Chem. Lett., 13, 1942
- Liu J.-J., 2003, Bioorg. Med. Chem. Lett., 13, 2468
- Yue E. W., 2002, J. Med. Chem., 45, 5248
- Lane M. E., 2001, Cancer Res., 61, 6177
- Andreani A., 2000, Anti-Cancer Drug Des., 15, 452
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3839
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3846
- Zhu G., 2003, Bioorg. Med. Chem. Lett., 13, 1235
- Ryu C.-K., 2000, Bioorg. Med. Chem. Lett., 10, 464
- Honma T., 2001, J. Med. Chem., 44, 4627
- Honma T., 2001, J. Med. Chem., 44, 4640
- Jeong H.-W., 2000, Bioorg. Med. Chem. Lett., 10, 1822
- Zhu G., 2003, J. Med. Chem., 46, 2030
- Bartek J., 2003, Biochem. J., 371, 204
- Bartkova J., 1997, Prog. Cell Cycle Res., 3, 220
- Hall M., 1996, Adv. Cancer Res., 68, 108
- Misra R. N., 2004, Chem
- Kelland L. R., 2000, Exp. Opin. Invest. Drugs, 9, 2911
- Chao S.-H., 2001, J. Biol. Chem., 276, 31799
- Chao S.-H., 2000, J. Biol. Chem., 275, 28348
- Tetsu O., 2003, Cancer Cell, 2, 245
- Fry D. W., 2004, Mol. Cancer Ther., 3, 1437
- Meyerson M., 1994, Mol. Cell Biol., 14, 2086
- Fry D. W., 1994, Anticancer Drug Des., 9, 351
- Fry D. W., 1997, Biochem. Pharmacol., 54, 887
Cited by
Items 101–200 of 555
Groenland, S. L., Martínez-Chávez, A., van Dongen, M. G. J., Beijnen, J. H., Schinkel, A. H., Huitema, A. D. R., & Steeghs, N. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00930-x · Cited by 121
Johnson, N., & Shapiro, G. I. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.525221 · Cited by 120
“Additionally, administration of PD0332991 at the time of therapeutic irradiation to TyrRasInk4a/Ar–/- mice, which harbor autochthonous melanomas, reduced treatment toxicity without compromising tumor therapeutic response.”
InfluentialSynergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Pikman, Y., Alexe, G., Roti, G., Conway, A. S., Furman, A. A., Lee, E. S., Place, A. E., Kim, S., Saran, C., Modiste, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2869 · Cited by 120
Toward Understanding the Structural Basis of Cyclin-Dependent Kinase 6 Specific Inhibition
Lu, H., & Schulze-Gahmen, U. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0600388 · Cited by 100
Choi, S., Lee, J., Jeong, S.-Y., Im, I., Lee, S., Lee, E.-J., Lee, S. K., Kwon, S., Ahn, S., Yoon, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100080z · Cited by 110
Chohan, T. A., Qayyum, A., Rehman, K., Tariq, M., & Akash, M. S. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.116 · Cited by 112
Turner, N. C., Finn, R. S., Martín, M., Im, S., DeMichele, A. M., Ettl, J., Dieras, V. C., Moulder, S., Lipatov, O. N., Colleoni, M. A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx797 · Cited by 100
“One such therapy is palbociclib, a first-in-class, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) [8, 9].”
BackgroundMiettinen, T. P., Peltier, J., Härtlova, A., Gierliński, M., Jansen, V. M., Trost, M., & Björklund, M. (2018) · The EMBO Journal · doi:10.15252/embj.201798359 · Cited by 101
Horiuchi, T., Chiba, J., Uoto, K., & Soga, T. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.090 · Cited by 108
Kumar, R. N., Dev, G. J., Ravikumar, N., Swaroop, D. K., Debanjan, B., Bharath, G., Narsaiah, B., Jain, S. N., & Rao, A. G. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.038 · Cited by 94
Saab, R. H., Bills, J. L., Miceli, A. P., Anderson, C., Khoury, J. D., Fry, D. W., Navid, F., Houghton, P. J., & Skapek, S. X. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0383 · Cited by 96
“PD 0332991 (32), provided by Pfizer Global R&D, Michigan Labs (Ann Arbor, MI), was resuspended in DMSO and used at a concentration of 1,000 nmol/L in cell culture medium.”
BackgroundMethodSelf-citation4-(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6
Cho, Y. S., Borland, M., Brain, C., Chen, C. H.-T., Cheng, H., Chopra, R., Chung, K., Groarke, J., He, G., Hou, Y., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100571n · Cited by 91
Iodine-124: A Promising Positron Emitter for Organic PET Chemistry
Koehler, L., Gagnon, K., McQuarrie, S. A., & Wuest, F. R. (2010) · Molecules · doi:10.3390/molecules15042686 · Cited by 95
“Based on selective Cdk4/6 inhibitors reported in the literature, two compounds were selected for radiolabeling via radioiodo-destannylation with iodine-124 [93,94].”
BackgroundPhase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
Tamura, K., Mukai, H., Naito, Y., Yonemori, K., Kodaira, M., Tanabe, Y., Yamamoto, N., Osera, S., Sasaki, M., Mori, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12932 · Cited by 92
Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications
Sofi, S., Mehraj, U., Qayoom, H., Aisha, S., Asdaq, S. M. B., Almilaibary, A., & Mir, M. A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01731-x · Cited by 100
“01 μM in vitro conditions, and exhibits high specificity when examining other 36 kinases, including CDK2 (IC50 > 5 μM) (Table 4) [76].”
BackgroundMEK drives cyclin D1 hyperelevation during geroconversion
Leontieva, O. V., Demidenko, Z. N., & Blagosklonny, M. V. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.86 · Cited by 94
“In order to develop an alternative model to IPTG-induced cyclin D1-positive senescence model (HT-p21 cells), we utilized PD0332991 that is a very selective inhibitor of CDK 4/6.(64) As expected, by inhibiting CDK4/6, PD0332991 inhibited proliferation of MEL10 cells (Figure 5a), but it did not inhibit phosphorylation o…”
MethodRugo, H. S., Turner, N. C., Finn, R. S., Joy, A. A., Verma, S., Harbeck, N., Masuda, N., Im, S., Huang, X., Kim, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.017 · Cited by 91
Transcription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 95
“Targeting only these CDKs in tumors that have CDK4/CDK6 dysregulation, causes arrest of the cell cycle mediated by retinoblastoma 1 (Malumbres et al., 2004; Toogood et al., 2005).”
BackgroundDeng, M., Lin, J., Nowsheen, S., Liu, T., Zhao, Y., Villalta, P. W., Sicard, D., Tschumperlin, D. J., Lee, S., Kim, J.-J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2630 · Cited by 99
“5 kPa and 1 kPa) exhibited a significantly decreased sensitivity to the cyclin-dependent kinase 4/6 inhibitor Palbociclib (34), suggesting that low stiffness specifically increases cellular sensitivity to DNA damaging agents (Fig.”
InfluentialDevelopment of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases
Schönbrunn, E., Betzi, S., Alam, R., Martin, M. P., Becker, A., Han, H., Francis, R., Chakrasali, R., Jakkaraj, S., Kazi, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301234k · Cited by 88
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Scott, S. C., Lee, S. S., & Abraham, J. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.006 · Cited by 96
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bolin, S., Borgenvik, A., Persson, C., Sundström, A., Qi, J., Bradner, J. E., Weiss, W. A., Cho, Y., Weishaupt, H., & Swartling, F. J. (2018) · Oncogene · doi:10.1038/s41388-018-0135-1 · Cited by 90
“1b, c) of normal NSCs and GTML2 cells following a 72 h treatment with BET bromodomain inhibitor JQ1, selective CDK2 inhibitor Milciclib [26], selective CDK4/6 inhibitor Palbociclib [27], or doxycycline (DOX) (Supplementary Figure 1c) showed an increased response to increasing concentration of the active compound.”
c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
Ji, W., Zhang, W., Wang, X., Shi, Y., Yang, F., Xie, H., Zhou, W., Wang, S., & Guan, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02980-2 · Cited by 94
Li, Y., Luo, X., Guo, Q., Nie, Y., Wang, T., Zhang, C., Huang, Z., Wang, X., Liu, Y., Chen, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00209 · Cited by 88
Medicinal chemistry perspective of pyrido[2,3- d ]pyrimidines as anticancer agents
Kumar, A., Bhagat, K. K., Singh, A. K., Singh, H., Angre, T. D., Verma, A., Khalilullah, H., Jaremko, M., Emwas, A.-H. M., & Kumar, P. (2023) · RSC Advances · doi:10.1039/d3ra00056g · Cited by 97
CDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 90
Xiong, R., Zhao, J., Gutgesell, L. M., Wang, Y., Lee, S., Karumudi, B., Zhao, H., Lu, Y., Tonetti, D. A., & Thatcher, G. R. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01355 · Cited by 110
Sun, W., Klamerus, K. J., Yuhas, L. M., Pawlak, S., Plotka, A., O’Gorman, M. T., Kirkovsky, L., Kosa, M. B., & Wang, D. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.356 · Cited by 82
Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents
Lin, R., Connolly, P. J., Lü, Y., Chiu, G., Li, S., Yu, Y., Huang, S., Li, X., Emanuel, S. L., Middleton, S. A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.029 · Cited by 80
Telezhkin, V., Schnell, C., Yarova, P., Yung, S., Cope, E. L., Hughes, A., Thompson, B. A. N., Sanders, P., Smith-Geater, C., Hancock, J. M., et al. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00166.2015 · Cited by 90
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 82
“The CDK4/6 inhibitor PD0332991 increases platinum efficacy in vivo We next moved in vivo and subcutaneously injected SKOV3ip or MDAH cells in nude mice, waited for tumor appearance (~50 mm3), and then treated mice with vehicle, platinum, PD, or their combination (Figs 3A and EV3A).”
MethodInfluentialCDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Palmer, C. L., Boras, B. W., Pascual, B., Li, N., Li, D., Garza, S. J., Huser, N. H., Yuan, J. T., Cianfrogna, J. A., Sung, T., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.006 · Cited by 85
Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells
The, I., Ruijtenberg, S., Bouchet, B. P., Cristobal, A., Prinsen, M. B. W., van Mourik, T., Koreth, J., Xu, H., Heck, A. J. R., Akhmanova, A. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms6906 · Cited by 86
Hino, H., Iriyama, N., Kokuba, H., Kazama, H., Moriya, S., Takano, N., Hiramoto, M., Aizawa, S., & Miyazawa, K. (2020) · Cancer Science · doi:10.1111/cas.14419 · Cited by 80
Vaughn, D. J., Hwang, W., Lal, P., Rosen, M. A., Gallagher, M., & O'Dwyer, P. J. (2015) · Cancer · doi:10.1002/cncr.29213 · Cited by 74
“GCT 8 (27) Normalized nuclear pRB score: Median [range] 120 [5-300]”
BackgroundCDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 80
“The position of the T172-phosphorylated CDK4 form (spot 3) is circled. ª 2017 The Authors EMBO Molecular Medicine Vol 9 | No 8 | 2017 close to the PD0332991 IC50 on CDK4 activity in vitro (11 nM; Toogood et al, 2005).”
BackgroundTadesse, S., Yu, M., Mekonnen, L. B., Lam, F., Islam, S., Tomusange, K., Rahaman, M. H., Noll, B. D., Basnet, S. K. C., Teo, T., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01670 · Cited by 82
Reddy, M. V. R., Akula, B., Cosenza, S. C., Divakar, S. K. A., Mallireddigari, M. R., Pallela, V. R., Billa, V. K., Subbaiah, D. R. C. V., Bharathi, E. V., Carpio, R. V., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401073p · Cited by 80
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 81
Składanowski, A., Bozko, P. M., & Sabisz, M. (2009) · Chemical Reviews · doi:10.1021/cr900026u · Cited by 77
Horiuchi, T., Nagata, M., Kitagawa, M., Akahane, K., & Uoto, K. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.10.039 · Cited by 75
Knudsen, E. S., Hutcheson, J., Vail, P. J., & Witkiewicz, A. K. (2017) · Oncotarget · doi:10.18632/oncotarget.18435 · Cited by 75
“Palbociclib and ribociclib are based off of a similar pyrido [2,3-d]pyrimidin-7-one scaffold that was optimized for selectivity toward CDK4/6 [1, 8-10].”
BackgroundSingh, U., Chashoo, G., Khan, S. U., Mahajan, P., Nargotra, A., Mahajan, G., Singh, A., Sharma, A., Mintoo, M. J., Guru, S. K., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00663 · Cited by 72
Targeted Protein Degradation Induced by HEMTACs Based on HSP90
Li, Z., Ma, S., Zhang, L., Zhang, S., Ma, Z., Du, L., & Li, M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01648 · Cited by 74
Schade, A. E., Oser, M. G., Nicholson, H. E., & DeCaprio, J. A. (2019) · Oncogene · doi:10.1038/s41388-019-0767-9 · Cited by 81
Shi, Z., Tian, L., Qiang, T., Li, J., Xing, Y. Q., Ren, X., Liu, C., & Liang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02064 · Cited by 72
Le, T. M., Poddar, S., Capri, J. R., Abt, E. R., Kim, W., Liu, W., Uong, N. T., Cheng, C., Braas, D., Nikanjam, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00221-3 · Cited by 75
Whiteway, S. L., Harris, P. S., Venkataraman, S., Alimova, I., Birks, D. K., Donson, A. M., Foreman, N. K., & Vibhakar, R. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1000-7 · Cited by 68
“PD0332991 is an orally available small molecule inhibitor that targets the kinase activity of CDK4 and CDK6 [9].”
BackgroundJenkins, P. R., Wilson, J., Emmerson, D. P. G., García, M. D., Smith, M. R., Gray, S. J., Britton, R. G., Mahale, S., & Chaudhuri, B. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.002 · Cited by 67
Bisteau, X., Paternot, S., Colleoni, B., Ecker, K., Coulonval, K., De Groote, P., Declercq, W., Hengst, L., & Roger, P. P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003546 · Cited by 65
“PD0332991 is a specific inhibitor of CDK4 and CDK6 and does not inhibit CDK2 and the proliferation of pRb-negative cells [27,70].”
BackgroundLiu, C., Lau, K.-Y., Hsu, C., Chen, J.-L., Lee, C.-H., Huang, T., Chen, Y., Huang, C.-T., Lin, P., & Tseng, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189007 · Cited by 71
Recent Advances and Perspectives in Cancer Drug Design
Magalhães, L. G., Ferreira, L. L. G., & Andricopulo, A. D. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170823 · Cited by 80
Niesvizky, R., Badros, A. Z., Costa, L. J., Ely, S. A., Singhal, S., Stadtmauer, E. A., Haideri, N. A., Yacoub, A., Heß, G., Lentzsch, S., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1030641 · Cited by 70
Regulation of senescence escape by the cdk4–EZH2–AP2M1 pathway in response to chemotherapy
Le Duff, M., Gouju, J., Jonchère, B., Guillon, J., Toutain, B., Boissard, A., Henry, C., Guette, C., Lelièvre, E., & Coqueret, O. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0209-y · Cited by 64
Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
Majumdar, A., Burban, D. J., Muretta, J. M., Thompson, A. R., Engel, T. A., Rasmussen, D. M., Subrahmanian, M. V., Veglia, G., Thomas, D. D., & Levinson, N. M. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00725-y · Cited by 65
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
Asciolla, J. J., Wu, X., Adamopoulos, C., Gavathiotis, E., & Poulikakos, P. I. (2025) · Nature Cancer · doi:10.1038/s43018-024-00893-z · Cited by 73
“All clinical CDK4/6 inhibitors potently bind and inhibit the highly active CDK4–cyclin D and CDK6–cyclin D complexes in vitro 1,41,76 , but the relative potency toward either CDK4 or CDK6 in their native states in cells varies.”
Cell Cycle Regulating Kinase Cdk4 as a Potential Target for Tumor Cell Treatment and Tumor Imaging
Graf, F., Koehler, L., Knieß, T., Wuest, F. R., Mosch, B., & Pietzsch, J. (2009) · Journal of Oncology · doi:10.1155/2009/106378 · Cited by 68
“[17, 18] identified various pyrido-[2,3-d]pyrimidin-7-ones derivatives as selective inhibitors of the Cdk4-cyclin D complex (IC50 2– 32 nM).”
Brasca, M. G., Albanese, C., Alzani, R., Amici, R., Avanzi, N. R., Ballinari, D., Bischoff, J. R., Borghi, D., Casale, E., Croci, V., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.042 · Cited by 61
Progress in the evaluation of CDK inhibitors as anti-tumor agents
McInnes, C. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.012 · Cited by 65
Radioprotection of normal tissue cells
Maier, P. J., Wenz, F. K., & Herskind, C. (2014) · Strahlentherapie und Onkologie · doi:10.1007/s00066-014-0637-x · Cited by 67
Ramsey, M. R., Krishnamurthy, J., Pei, X.-H., Torrice, C., Lin, W., Carrasco, D. R., Ligon, K. L., Xiong, Y., & Sharpless, N. E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3437 · Cited by 61
“0332991, a specific inhibitor of cdk4/6, but not cdk2 or other tested kinases (38).”
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 71
Chen, L., & Pan, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13836 · Cited by 60
“PD-0332991 (palbociclib) is an orally available, highly specific and reversible inhibitor of both CDK4 and CDK6 kinase activities (Toogood et al., 2005).”
BackgroundLatif, N. A. A., Batran, R. Z., Khedr, M. A., & Abdalla, M. M. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.06.005 · Cited by 62
Cancer takes many paths through G1/S
Knudsen, E. S., Witkiewicz, A. K., & Rubin, S. M. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.10.007 · Cited by 62
Anticancer Activity of Pyrazole via Different Biological Mechanisms
Chauhan, S., Paliwal, S., & Chauhan, R. (2014) · Synthetic Communications · doi:10.1080/00397911.2013.837186 · Cited by 57
Kemp, P. J., Rushton, D. J., Yarova, P. L., Schnell, C., Geater, C., Hancock, J. M., Wieland, A., Hughes, A., Badder, L., Cope, E., et al. (2016) · The Journal of Physiology · doi:10.1113/jp270655 · Cited by 55
“However, there were no data presented regarding potential synchronization and it might be more prudent to use both PD0332991 with DAPT, as we have now shown (Telezhkin et al. , 2016).”
Li, M., Zhong, A., Wu, Y., Sidharta, M., Beaury, M. W., Zhao, X., Studer, L., & Zhou, T. (2022) · Nature Communications · doi:10.1038/s41467-022-34045-7 · Cited by 61
N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine
Bettayeb, K., Sallam, H., Ferandin, Y., Popowycz, F., Fournet, G., Hassan, M., Echalier, A., Bernard, P., Endicott, J., Joseph, B., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0080 · Cited by 63
“11, 12), R547 (13, 14), SNS-032 (15), PD-0332991 (16, 17), AZD5438 (18, 19), ZK 304709 (20, 21), AG-024322, AT7519, and P27600 (21).”
Kumar, K. S. S., Ananda, H., Hegde, M. B., Narasimhamurthy, K. H., Raghavan, S. C., & Rangappa, K. S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.009 · Cited by 55
Göttgens, E., Bussink, J., Leszczyńska, K. B., Peters, H., Span, P. N., & Hammond, E. M. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.06.2531 · Cited by 59
Yin, L., Li, H., Liu, W., Yao, Z., Cheng, Z., Zhang, H., & Zou, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.003 · Cited by 54
Emerging Links between E2F Control and Mitochondrial Function
Benevolenskaya, E. V., & Frolov, M. V. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2173 · Cited by 65
“This idea is especially relevant given the recent success of a small-molecule CDK4/6 inhibitor, PD0332991, in clinical trials (33).”
BackgroundCho, Y. S., Angove, H. C., Brain, C. T., Chen, C. H.-T., Cheng, H., Cheng, R., Chopra, R., Chung, K., Congreve, M., Dagostin, C., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200241a · Cited by 53
Recent Advances in CDK Inhibitors for Cancer Therapy
Heptinstall, A. B., Adiyasa, I., Cano, C., & Hardcastle, I. R. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0246 · Cited by 56
Saleem, H., Abdul, U. K., Küçükosmanoğlu, A., Houweling, M., Cornelissen, F. M. G., Heiland, D. H., Hegi, M. E., Kouwenhoven, M. C. M., Bailey, D. S., Würdinger, T., et al. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.04.002 · Cited by 59
Structure-based discovery of cyclin-dependent protein kinase inhibitors
Martin, M. P., Endicott, J., & Noble, M. E. M. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170040 · Cited by 56
“Although no structures have been reported for such inhibitors bound to CDK4/6-cyclin D complexes, drug discovery programs have developed CDK4/6-selective inhibitors of which two, ribociclib [69] and palbociclib [33] are approved for the treatment of hormone receptor positive and human epidermal growth factor receptor-…”
Sun, W., O'Dwyer, P. J., Finn, R. S., Ruiz-García, A., Shapiro, G. I., Schwartz, G. K., DeMichele, A. M., & Wang, D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.902 · Cited by 50
Cheng, C., Yun, F., Ullah, S., & Yuan, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112073 · Cited by 52
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
Susanti, N. M. P., & Tjahjono, D. H. (2021) · Molecules · doi:10.3390/molecules26154462 · Cited by 54
“Moreover, a flavone compound from Urginea indica bulbs tends to stimulate apoptosis, G0/G1phase arrest, and also inhibits angiogenesis in breast cancer cells by restricting CDK1 and CDK6 [115].”
BackgroundFascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1
Aubry, C., Wilson, A. J., Emmerson, D. P. G., Murphy, E. J., Chan, Y. Y., Dickens, M. P., García, M. D., Jenkins, P. R., Mahale, S., & Chaudhuri, B. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.06.070 · Cited by 48
Benson, D. M., Yu, J., Becknell, B., Wei, M., Freud, A. G., Ferketich, A. K., Trotta, R., Perrotti, D., Briesewitz, R., & Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2008-05-159285 · Cited by 48
“when cells were exposed to a selective CDK4 inhibitor (PD0332991) prior to cytokine stimulation.(19,20) The modest proliferation mediated by SCF alone fell 13% (p < 0.”
BackgroundOngoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
Başaran, G., Twelves, C. J., Dieras, V. C., Cortés, J., & Awada, A. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.002 · Cited by 51
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 55
“Selective targeting of CDK4/6 by the ATP-competitive inhibitors palbociclib [60], abemaciclib [61] and ribociclib [62] induces cell cycle arrest via prevention of Rb phosphorylation (Figure 3a).”
BackgroundRajan, M., Praphakar, R. A., Govindaraj, D., Arulselvan, P., & Kumar, S. S. (2017) · Materials Today Chemistry · doi:10.1016/j.mtchem.2017.08.002 · Cited by 46
Maskey, R. S., Wang, F., Lehman, E., Wang, Y., Emmanuel, N., Zhong, W., Jin, G., Abraham, R. T., Arndt, K. T., Myers, J. S., et al. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1859195 · Cited by 51
“Palbociclib, a potent and highly selective inhibitor of CDK4/CDK6 [5], was the first CDK inhibitor to be approved for the treatment of ER +/HER2- breast cancer in combination with endocrine therapy [6].”
BackgroundCyclin degradation for cancer therapy and chemoprevention
Freemantle, S. J., Liu, X., Feng, Q., Galimberti, F., Blumen, S. R., Sekula, D., Kitareewan, S., Dragnev, K. H., & Dmitrovsky, E. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21519 · Cited by 46
“A long-standing goal has been to obtain specific CDK4/6 inhib- itors and that objective is being addressed by several small molecule and natural product inhibitors, for example, PD 0332991, fascaplysin and fascaplysin analogues [Toogood et al., 2005; Mahale et al., 2006; Lin et al., 2007].”
BackgroundPalbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Morikawa, A., & Henry, N. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0390 · Cited by 50
“During its development, this compound was selected for its CDK4/6 specificity and showed equivalent potency for CDK4 and CDK6 (10).”
BackgroundAbbas, S. E.-S., George, R. F., Samir, E. M., Aref, M. M. A., & Abdel‐Aziz, H. A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0050 · Cited by 45
Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
Pennycook, B. R., & Barr, A. R. (2021) · Open Biology · doi:10.1098/rsob.210125 · Cited by 49
“Our first assumption, based on canonical models of cell cycle entry, is direct CDK4/6 kinase inhibition resulting in cell cycle arrest [4,15,31].”
BackgroundAlinari, L., Prince, C. J., Edwards, R. B., Towns, W. H., Mani, R., Lehman, A., Zhang, X., Jarjoura, D. G., Pan, L., Kinghorn, A. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0839 · Cited by 48
Anwer, M. K., Fatima, F., Ahmed, M. M., Aldawsari, M. F., Alali, A. S., Kalam, M. A., Alshamsan, A., Alkholief, M. A., Malik, A., Alanazi, A. Z., et al. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.03.019 · Cited by 45
“In 2004, palbociclib (PD-0332991) was reported as the first CDK4/CDK6-specific inhibitor (Toogood et al. 2005).”
Estepa‐Fernández, A., García‐Fernández, A., Lérida‐Viso, A., Blandez, J. F., Galiana, I., Sancenón, F., Orzáez, M., & Martínez‐Máñez, R. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106628 · Cited by 43
The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
Paternot, S., Bianca, C., Bisteau, X., & Roger, P. P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.946841 · Cited by 46
Traquandi, G., Ciomei, M., Ballinari, D., Casale, E., Colombo, N., Croci, V., Fiorentini, F., Isacchi, A., Longo, A., Mercurio, C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901710h · Cited by 42
Woodward, H. L., Innocenti, P., Cheung, K.-M. J., Hayes, A., Roberts, J., Henley, A. T., Faisal, A., Mak, G. W.-Y., Box, G., Westwood, I. M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00690 · Cited by 40
Dwyer, M. P., Paruch, K., Alvarez, C., Doll, R. J., Keertikar, K. M., Duca, J. S., Fischmann, T. O., Hruza, A. W., Madison, V., Lees, E. M., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.018 · Cited by 45
Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011–2023
Romanelli, M. N., Braconi, L., Gabellini, A., Manetti, D., Marotta, G., & Teodori, E. (2023) · Molecules · doi:10.3390/molecules29010068 · Cited by 40
“Both aryl groups on the piperazine N-atoms are aza-heterocycles, making SN Ar reactions feasible. and ethyl 2-chloropyrimidine-5-carboxylate.”
BackgroundMahale, S., Bharate, S. B., Manda, S., Joshi, P., Bharate, S. S., Jenkins, P. R., Vishwakarma, R. A., & Chaudhuri, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5014743 · Cited by 42
Duan, S., Place, D. W., Perfect, H. H., Ide, N. D., Maloney, M. T., Sutherland, K., Wiglesworth, K. E. P., Wang, K., Olivier, M., Kong, F., et al. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00070 · Cited by 40
Metadata
- Authors
- Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., Brodfuehrer, J., Choi, C., Barvian, M. R., & Fry, D. W.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Toogood, Peter L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-03-02
- Volume
- 48
- Issue
- 7
- Pages
- 2388-2406
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1985389450
- Cited by
- 513
- References
- 50
- Citations by year
- 2026: 23 · 2025: 41 · 2024: 20 · 2023: 25 · 2022: 38 · 2021: 32 · 2020: 32 · 2019: 30 · 2018: 44 · 2017: 42 · 2016: 34 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 17
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6, CDK4/6 inhibitors, kinase selectivity, G1 cell cycle arrest, palbociclib, small-molecule kinase inhibitors, anticancer drug candidates, pharmacokinetics
- MeSH terms
- Animals, Antineoplastic Agents, Biological Availability, Humans, Male, Piperazines, Proto-Oncogene Proteins, Pyridines, Pyrimidines, Structure-Activity Relationship, Thymidine, G1 Phase, Rats, Sprague-Dawley, Cyclin-Dependent Kinases, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.